Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SciClone China CEO Mark Lotter On The Changing Commercial Landscape: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Considered one of the top commercial minds in China, the former AstraZeneca exec and founder of NovaMed discusses how to build a sustainable commercial model in a rapidly changing China, touching on everything from retaining talent to surviving China’s latest round of price cuts.

You may also be interested in...



Could Less Enforcement Action Of Foreign Corrupt Practices Act Mean Compliance Is Improving?

HONG KONG - Enforcement of anti-corruption legislation remains strong but nowhere near the publicly aggressive levels of 2010. This year is on track to beat 2009 and maintain the upward trend in the number of actions and the size of the fines levied by authorities in the United States under the Foreign Corrupt Practices Act, according to Arnold & Porter, a U.S. law firm

With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics

SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts

China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed

SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18

Topics

Related Companies

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel